Journal article
Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy
British journal of ophthalmology, v 79(4), pp 306-312
Apr 1995
PMID: 7742272
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
BACKGROUND--Plaque radiotherapy is the most common method of managing posterior uveal melanoma but its use for iris melanoma and iris metastases has not yet been evaluated. METHODS--Fourteen patients with non-resectable iris melanoma and four with iris metastasis were treated with plaque radiotherapy. The tumour response to treatment and the local side effects of the radioactive plaque were evaluated. RESULTS--In the iris melanoma group over a mean follow up of 26 (range 6-75) months, the tumour regressed in 13 of the 14 patients (93%) and recurred as diffuse seeding in one patient (7%). Despite large doses of radiation given transcorneally, the cornea developed epitheliopathy, abrasion, and oedema in only one case each. The major radiation side effects were localised iris vasculopathy without glaucoma in two cases, posterior synechiae in five cases, and cataract in six cases. In the iris metastasis group, tumour regression was observed in all four patients (100%) and radiation side effects were not evident over the relatively short mean follow up period of 8 (range 4-9) months. All of the 14 patients with irradiated iris melanoma have remained systemically healthy without metastasis while three of the four patients with irradiated iris metastases have died of metastases from the primary neoplasm. CONCLUSION--Custom designed plaque radiotherapy appears to be an effective alternative method of controlling non-resectable diffuse iris melanoma and solitary iris metastasis and has relatively few side effects.
Metrics
Details
- Title
- Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy
- Creators
- C L Shields - Wills Eye HospitalJ A Shields - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USAP De Potter - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USAA D Singh - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USAC Hernandez - Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USAL W Brady - Thomas Jefferson University
- Publication Details
- British journal of ophthalmology, v 79(4), pp 306-312
- Publisher
- BMJ Publishing Group Ltd
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Psychiatry; Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:A1995QT21800003
- Scopus ID
- 2-s2.0-0028906142
- Other Identifier
- 991019183939404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Ophthalmology